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Do neuroendocrine cells come up large in small cell lung cancer?
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Most organs of the body can develop tumors 
of different histological subtypes that often 
show distinct biologic behavior and respond 
differently to various therapeutic modalities. 
Understanding the cellular and molecular 
components driving each subtype will make 
it possible to develop specific targeted thera-
pies tailored to each tumor type to maximize 
therapeutic efficacy and minimize side effects. 
One critical issue is whether distinct tumor 
subtypes arising in the same organ originate 
from distinct cell types or from a common cell 
of origin. Two recent studies, including the one 
from Carla Kim, Julien sage and colleagues,1 
use mouse models to demonstrate that small 
cell lung cancer (sCLC) does not arise from 
the same cell of origin as non-small cell lung 
cancer (NsCLC). while NsCLC can arise from 
transformed Clara cell-specific protein (CCsP)-
expressing cells,2 sCLC most likely arises from 
CCsP-negative neuroendocrine (Ne) cells.
sCLC is an aggressive, less common histo-
logical subtype of lung cancer composed of 
highly proliferative tumor cells showing mor-
phological features of Ne cells and expressing 
Ne markers, including synaptophysin, chro-
mogranin and Calcitonin gene-related protein 
(CGRP). sCLC is associated with mutations in 
tumor suppressor genes Rb and p53 and is 
histologically and molecularly distinct from 
the more common NsCLC, which is often char-
acterized by mutations in K-ras and expression 
of the alveolar type ii (AT-2) marker surfactant 
protein C (sP-C).4
Park et al. and sutherland et al. demon-
strated that deletion of Rb and p53 in all cells 
led to proliferating Ne-like lesions and sCLC.1,4 
when Rb and p53 were deleted specifically 
in CCsP-expressing cells, excluding Ne cells 
and predominantly targeting the Clara cell 
lineage, sCLC was not observed.1,4 since CCsP-
expressing cells can initiate NsCLC but not 
sCLC, the lung must contain multiple cell pop-
ulations that are susceptible to transformation.
The main inconsistency between the two 
studies is presented when Rb and p53 were 
deleted in sP-C+ cells, predominantly rep-
resenting the alveolar lineage. Kim and col-
leagues observed the development of rare 
adenocarcinoma, but not sCLC, when using 
both adenoviral delivery and a double-trans-
genic approach to delete Rb and p53 in alveo-
lar cells.1 in contrast, sutherland et al. reported 
that 50% of animals developed sCLC after loss 
of Rb and p53 in cells expressing sP-C, but the 
tumors took longer to develop than for those 
initiated in CGRP+ Ne cells.4
sutherland et al. showed that CGRP+ Ne 
cells were the most efficient cells of origin for 
sCLC, although other cell types could also con-
tribute to disease initiation.4 Park et al. exclude 
non-Ne cell types (CCsP+ and sP-C+ cells) in 
the initiation of sCLC but do not definitively 
demonstrate a Ne cell origin,1 leaving open 
the possibility of a yet-to-be-discovered cell of 
origin. This emerging concept that tumors of 
different histological types arising in the same 
organ may originate from different adult tissue 
cell types is also supported by recent evidence 
in breast cancer.5
After lung cancer, the most common can-
cer site for males is the prostate, with the 
acinar type adenocarcinoma being the pre-
dominant histologic type. Prostatic small cell 
neuroendocrine carcinoma (sCNC) is a rare 
histological variant that is distinguished by 
proliferating Ne-like cells.6 sCNC is aggressive 
and does not respond to hormonal therapy 
in contrast to adenocarcinoma comprised of 
luminal type tumor cells. Deletion of the same 
tumor suppressor pathways (Rb and p53) in 
the prostate7 leads to sCNC-like lesions. we 
recently showed that target cells expressing 
basal cell markers, which are generally absent 
from prostate adenocarcinoma, are efficient 
cells of origin for luminal type prostate adeno-
carcinoma.8 Basal stem/progenitor cells in the 
prostate have the capacity to differentiate 
into Ne cells,9 suggesting that they may also 
be capable of sCNC initiation. Another pos-
sibility is that Ne cells, a component of normal 
human prostate and adenocarcinoma, can ini-
tiate sCNC in the prostate, similar to results by 
Berns and colleagues.3
These important studies demonstrate that 
different histological subtypes of lung cancer 
can arise from distinct cell types. This principle 
is likely to hold true in tumors arising in other 
organs. Further interrogation of different tar-
get cells and the mechanisms that they utilize 
during progression to distinct cancer types 
may inform the development of future bio-
markers to monitor the disease and potentially 
lead to new therapeutic targets.
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sUMO is a small protein that can be con-
jugated to other proteins and subsequently 
modulates their functions. The effects of 
sUMO on target proteins can be diverse and 
dynamic, making it a useful means for alter-
ing protein functions and regulating cellular 
pathways. sUMO plays an important role in 
genome maintenance. Multiple studies have 
shown that mutating sumoylation or desu-
moylation enzymes can lead to sensitivity to 
DNA damaging agents as well as defects in 
double-strand DNA break repair and in the 
maintenance of specific genomic regions.1 The 
underlying mechanisms accounting for these 
defects have begun to emerge from studies on 
how sUMO modification alters the functions of 
DNA metabolism enzymes and how proteins 
that can noncovalently bind to sUMO influ-
ence repair processes.
elg1 is the large subunit of one of the 
three alternative replication factor C (RFC) 
complexes.2 Because the canonical RFC loads 
PCNA, which facilitates DNA polymerases and 
docks other DNA processing enzymes on DNA, 
elg1-RFC is also thought to influence PCNA 
functions. interestingly, the budding yeast 
elg1 contains three sUMO interacting motifs 
(siMs) at its N-terminal region and nonco-
valently binds to sUMO.3 Recent work has 
suggested that the yeast elg1 preferentially 
binds to sumoylated PCNA and may help to 
unload this form of PCNA from chromatin.3 
As sumoylated PCNA can interact with the 
anti-recombinase srs2, the potential removal 
of sUMO-PCNA by elg1 could bias towards the 
use of recombinational repair over other types 
of repair, particularly those mediated by PCNA 
ubiquitination.
in the september 1st issue of Cell 
Cycle, Parnas and colleagues described 
the identification of seven additional elg1-
interacting proteins using a yeast two-hybrid 
screen.4 Like elg1, the seven proteins all con-
tain siMs and are previously identified sUMO 
interactors.5 This finding raises the possibil-
ity that the observed elg1 interactions with 
siM-containing proteins are bridged by poly-
sumoylated proteins. in support of this idea, 
the authors showed that fragments containing 
the siMs of the seven elg1-interacting proteins 
can associate with elg1, and at least one of 
these interactions requires poly-sumoylation. 
Although the bridging protein(s) are yet to 
be identified, the authors show that it is not 
PCNA.
Bridging protein-protein interactions is a 
reccurring theme for sUMO’s effects. For exam-
ple, sUMO was found to mediate multilateral 
protein interactions required for PML body 
formation.6 This work by Parnas et al. suggests 
that elg1 may exert some of its effects via 
interactions with other siM-containing pro-
teins. However, since mutants of most of the 
identified elg1 interactors do not exhibit a 
phenotype similar to elg1∆, they may not be 
the physiological elg1 partners.
One potential exception is the slx5/8 com-
plex, which also affects genomic stability. The 
best-characterized biochemical activity of 
the slx5/8 complex is as a ubiquitin ligase 
function with a higher affinity for sumoylated 
proteins.7,8 A phenotype often indicative of 
mutants defective in this type of ubiquitin 
ligase function is the accumulation of poly-
sumoylated proteins. However, unlike slx5∆ 
or slx8∆, elg1∆ cells do not exhibit this defect. 
Conversely, unlike elg1∆, slx5∆ cells contain 
normal levels of sumoylated PCNA. These 
results as well as other tests, including recom-
bination and mutation assays, suggest that 
elg1 and the slx5/8 complex have non-over-
lapping functions. Therefore, the physiologi-
cal role of the sUMO-mediated elg1-slx5/8 
interaction remains to be determined. Genetic 
studies using alleles that specifically impair 
this interaction will be informative. in addi-
tion, seeking the sumoylated bridging pro-
teins that mediate the interaction between 
elg1 and slx5/8 will also provide important 
clues about their roles in genome mainte-
nance. Nevertheless, this work suggests that 
some aspects of elg1’s function may rely on its 
interaction with other sUMO interactors. since 
the lack of human elg1 leads to a set of defects 
similar to those seen in yeast elg1∆ cells,9 it will 
be interesting to consider the greater impact 
of the potential ability of elg1 to interact with 
other sUMO interactors.
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Caveolin-1: A new therapeutic target in tissue fibrosis and scleroderma?
Comment on: Castello-Cros R, et al. Cell Cycle 2011; 10:2140–50 
Francesco Del Galdo; University of Leeds; Leeds, UK; Email: f.delgaldo@leeds.ac.uk; http://dx.doi.org/10.4161/cc.10.21.18033
scleroderma or systemic sclerosis (ssc) is the 
most common systemic fibrotic disease. its 
puzzling pathogenesis, including tissue fibro-
sis, fibroproliferative vasculopathy and autoim-
mune activation, has yet to be unraveled and 
is still an open challenge for the scientific com-
munity.1 As a consequence, the clinical man-
agement of patients affected by this condition 
is still devoid of effective interventions able to 
block the progression of the tissue fibrosis.2
in the last decade, several factors and sig-
naling pathways have been implicated in the 
pathogenesis of tissue fibrosis.3 Conflicting 
studies from different group may reflect (1) the 
lack of a comprehensive experimental model 
for scleroderma and/or (2) redundancy in the 
mechanism(s) that lead to tissue fibrosis.
The latter is a more likely explanation in 
light of recent studies linking caveolin-1 down-
regulation with tissue fibrosis in scleroderma as 
well as other fibrotic conditions.4,5 Caveolin-1 
(Cav-1) is the major coat protein of caveolar 
lipid rafts. These flask-shaped plasma mem-
brane invaginations function as microdomains 
that are able to integrate and regulate the sig-
naling of receptor-ligand complexes, including 
TGF-β,5 PDGF, veGF6 and endothelin.7 These 
pathways have all been shown to promote the 
pathogenesis of ssc.3 Moreover, mice lacking 
caveolin-1 develop skin and lung tissue fibro-
sis and pulmonary artery hypertension, all the 
major clinical hallmarks associated with sclero-
derma.4,5 A recent article by Castello-Cros et 
al. provides further evidence for the use of 
Cav-1-knockout mice as an accurate pre-clin-
ical model for scleroderma. The authors show 
that tissue fibrosis observed in Cav-1-null mice 
is accompanied by decreased collagen fiber 
diameter and increased tensile strength in the 
skin, both well-known characteristics of sclero-
derma. indeed, the observation that a single 
gene defect causes such a dramatic structural 
change in overall skin architecture highlights 
the importance of caveolin-1 in regulating 
extracellular matrix homeostasis. Most impor-
tantly, the study by Castello-Cros et al. also 
opens two new venues of investigation in ssc 
that were not previously considered.
The first is that lack of caveolin-1 expres-
sion may be causing the subtle chronic tis-
sue inflammation observed in ssc. Previous 
hypotheses regarding the pathogenesis of 
scleroderma have focused on autoimmune 
activation as the primary event in scleroderma, 
which, in turn, causes profibrotic activation 
and vasculopathy.1
Caveolin-knockout mice do not display 
autoantibodies nor other signs of autoimmu-
nity. However, in the manuscript by Castello-
Cros et al., the authors observed an increased 
number of tissue macrophages and mast cells 
in the skin. in this regard, it is interesting to 
speculate that fibroblastic changes in sclero-
derma (e.g., decreased caveolin-1 expression) 
may drive the autoimmune reaction rather 
than being its consequence.
A second important point is the observa-
tion of autophagic and mitophagic features in 
tissue fibroblasts from Cav-1-knockout mice. 
Recent studies have stressed the importance of 
autophagy in the “lethal” cancer microenviron-
ment.8 Given the known similarities between 
cancer-associated fibroblasts and profibrotic 
fibroblasts,9 it is likely that cancer-associated 
fibroblasts and Cav-1-negative fibroblasts in 
scleroderma patients display a similar meta-
bolic signature. The exact role of this metabolic 
shift in promoting the profibrotic phenotype 
has yet to be determined, but these new 
findings may lead to innovative therapeutic 
approaches for targeting tissue fibrosis.
References
1. Jimenez sA, et al. Ann intern Med 2004; 140:37-50; 
PMiD:14706971.
2. Kowal-Bielecka O, et al. Ann Rheum Dis 2009; 
68:620-8; PMiD:19147617; http://dx.doi.
org/10.1136/ard.2008.096677.
3. Gabrielli A, et al. N engl J Med 2009; 360:1989-
2003; PMiD:19420368; http://dx.doi.org/10.1056/
NeJMra0806188.
4. Del Galdo F, et al. Curr Opin Rheumatol 2008; 
20:713-9; PMiD:18949888; http://dx.doi.
org/10.1097/BOR.0b013e3283103d27.
5. Del Galdo F, et al. Arthritis Rheum 2008; 58:2854-
65; PMiD:18759267; http://dx.doi.org/10.1002/
art.23791.
6. Tahir sA, et al. Cancer Biol Ther 2009; 2009:2286-96.
7. Hassan Gs, et al. Am J Physiol Heart Circ Physiol 
2006; 290:H2393-401; PMiD:16415072; http://
dx.doi.org/10.1152/ajpheart.01161.2005.
8. witkiewicz AK, et al. Cell Cycle 2011; 10:1794-
809; PMiD:21521946; http://dx.doi.org/10.4161/
cc.10.11.15675.
9. sotgia F, et al. Am J Pathol 2009; 174:746-61; 
PMiD:19234134; http://dx.doi.org/10.2353/
ajpath.2009.080658.
Neuroendocrine cells: Potential cells of origin for small cell lung carcinoma
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small cell lung carcinoma (sCLC) is the most 
aggressive type of lung cancer, accounting for 
at least 14% of new lung cancer cases.1 sCLC 
is characterized by expression of neuroendo-
crine markers, such as synaptophysin and cal-
citonin gene-related peptide. However, about 
10% of sCLCs have areas of other lung cancer 
types, such as squamous cell carcinoma and 
adenocarcinoma. This observation suggests 
that, in addition to neuroendocrine cells, sCLC 
may originate from some not-yet-identified, 
multi-/bipotent stem/progenitor cells, which 
are able to differentiate into several cell types, 
including neuroendocrine cells. Alternatively, 
sCLC may be a result of phenotypical plasticity 
of other pulmonary non-neuroendocrine cells, 
such as Clara cells, which can generate cili-
ated cells of the lower airways, alveolar type 2 
(AT2) cells, which are able to differentiate 
toward alveolar type 1 (AT1) cells of the alveo-
lar ducts and acini or bronchio-alveolar stem 
cells (BAsCs), which can give rise to Clara, AT1 
and AT2 cells (Fig. 1).
in their study, groups led by Julien sage 
and Carla Kim2 addressed the issue of the 
cell of sCLC origin by taking advantage of 
previous observations that Cre-loxP-mediated 
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Figure 1. Models of potential origin of sCLC. Model 1 proposes that unipotent stem/progenitor 
cells or mature cells of neuroendocrine cell lineage give rise to sCLC. This model anticipates that 
cells lacking p53 and Rb may differentiate toward other types of lung cancer, such as adenocarci-
noma and squamous cell carcinoma in some cases. Model 2 proposes that sCLC arises from  
stem/progenitor cells able to differentiate toward several cell types, including neuroendocrine 
cells. Model 3 suggests that at least some of sCLCs could arise from non-neuroendocrine cell 
lineages due to differentiation plasticity of cells deficient for p53 and Rb.
inactivation of the tumor suppressor genes 
p53 and Rb in mouse lungs resulted in neu-
roendocrine malignancies closely resembling 
human sCLC according to their morphologi-
cal and molecular properties.3 since p53 and 
Rb alterations are among the most common 
mutations in human sCLC,1 this mouse model 
is likely to accurately reflect many facets of the 
disease pathogenesis.
By expressing Cre recombinase in differ-
ent cell types of the lung, the authors deter-
mined that neither Clara cells nor AT2 cells 
nor BAsCs gave rise to neuroendocrine neo-
plasms. The authors concluded that neu-
roendocrine cells were the most likely cells 
of origin of sCLC. A similar conclusion was 
recently reached by the group of Anton Berns.4 
However, at variance with the study by Park 
et al.,2 sutherland et al.4 observed that dele-
tion of p53 and Rb in AT2 cells does result in 
neuroendocrine neoplasms, albeit at lower 
rate (45 vs. 83%) and after increased median 
latency (452 vs. 362 d), as compared with 
neuroendocrine cell-specific deletion of these 
genes. As Park et al. note, the difference in 
observations can be explained by different 
efficiency of adenoviruses used by the two 
groups. However, it is less clear why mice 
expressing Cre under the control of AT2 and 
BAsC-specific surfactant protein C (sPC) pro-
moter have not developed neuroendocrine 
neoplasms similar to those initiated by sPC-
Cre adenovirus used by sutherland et al. and 
Park et al. propose that constitutive deletion 
of p53 and Rb in transgenic mice may affect 
lung cells differently than acute deletion of 
these genes after administration of sPC-Cre 
adenovirus. it is also possible that unlike the 
4.8 kb fragment of mouse sPC promoter used 
in the adenoviral vector, the 3.7 kb human sPC 
promoter fragment used in transgenic mice 
does not drive Cre expression in cells capable 
of neuroendocrine differentiation. Another 
possibility is that the high levels of adenoviral 
infection may affect the degree of cell suscep-
tibility to increased differentiation plasticity 
after p53 and Rb inactivation, either directly 
or by initiating microenvironmental changes. 
Finally, a difference in genetic backgrounds 
of mice used by different groups could be 
a possible reason. Future studies based on 
additional, preferably not adenovirus-based, 
systems should clarify this discrepancy.
Taken together, the studies by Park et al. 
and sutherland et al. make an important step 
toward better understanding of sCLC patho-
genesis by strengthening the possibility that 
neuroendocrine cell lineage is the primary 
source of sCLC while convincingly excluding 
Clara cells as a potential cell of origin. At the 
same time, these studies also highlight the 
need for better tools allowing characterization 
of pulmonary neuroendocrine cell lineage dur-
ing ontogenesis. A recent report has indicated 
the existence of mouse embryonic stem/pro-
genitor cells, which are able to differentiate 
toward all epithelial cell types, including neu-
roendocrine cells.5 Unfortunately, there has 
been no direct evidence that neuroendocrine 
cells are among the progeny of recently identi-
fied putative mouse adult lung stem/progeni-
tor cells.6,7 it is likely that further progress in 
these areas will firmly establish the cell of 
origin for sCLC, thereby facilitating develop-
ment of new rationally designed diagnostics 
and therapeutics.
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The importance of mitochondrial fusion in aging
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increasing evidences indicates that mitochon-
dria, besides their role in supplying cells with 
ATP through oxidative phosphorylation, play 
a relevant role in the regulation of apoptosis 
and cellular aging from mammals to yeast. 
Mitochondria are highly dynamic organelles 
whose number, morphology and distribution 
change in response to cellular activity, nutri-
tional status and developmental programs. 
Mitochondrial dynamicity involves two oppo-
site events, namely fission and fusion, and 
intrinsic or extrinsic disturbance of such pro-
cesses might results in cellular physiological 
alterations and diseases. 
As an example, the autosomal dominant 
optic atrophy and the neurodegenerative 
Charcot-Marie-Tooth disease type 2A are linked 
to mutations in the OPA1 and MFN2 genes 
encoding components of the inner and outer 
membrane fusion machinery, respectively.1
in S. cerevisiae, mitochondrial functions are 
dispensable and viable mutants can be culti-
vated under fermentative conditions. For this 
reason, yeast represents an easy and powerful 
model for the study of the dynamics of mito-
chondria. Moreover, yeast is a useful model 
organism also to study apoptosis and aging, 
and mitochondrial dynamics were shown to 
play a role in both processes.2
The use of yeast mutants allowed the iden-
tification of FZO1, MGM1 and UGO1 as the 
main genes controlling mitochondrial fusion. 
yeast FZO1 (mitofusin) encodes an evo-
lutionary conserved GTPases associated to a 
complex localized in the outer mitochondrial 
membrane.
MGM1 encodes a dynamin-related GTPase 
corresponding to mammalian OPA1.
UGO1 encodes a protein, up to now 
described only in fungi, supposed to be the 
connector between the products of the FZO1 
and MGM1 genes. 
Mutants in these genes share a similar phe-
notype consisting in the presence of highly 
fragmented mitochondria resulting from the 
impairment of fusion events counteracting the 
fission machinery.3,4
it has been reported that aging yeast cells 
show a reduction of the mitochondrial tubular 
network and that the promotion of mitochon-
drial fusion, caused by the deletion of DNM1 or 
by the incubation of cells with specific drugs, 
led to an increased lifespan.5-8
since the absence of OPA1 is lethal in mam-
malian cells, an interesting contribution to this 
field comes from a recent paper by Oisenwacz 
and colleagues, published in Cell Cycle, who 
studied in yeast cells the effect of the absence 
of Mgm1 (OPA1) during aging.  The authors, 
after separation of young and aged cells by elu-
triation, demonstrated that in MGM1 mutants, 
that show unopposed mitochondrial fission, 
there is no difference in the distribution of 
mitochondrial morphotypes between young 
and old cells, as more than 95% of them con-
tains fragmented mitochondria.  On the con-
trary, wild-type young cells essentially show 
mitochondrial tubular network with reduced 
fragmentation, a phenomenon that increases 
significantly in stationary phase aging cells.
Linked to the aberrant mitochondrial mor-
phology, the absence of Mgm1 negatively 
influences both chronological and replicative 
lifespan in yeast. Moreover, mgm1 mutant 
cells are more susceptible to the induction of 
apoptosis by hydrogen peroxide.9 
These results, obtained with yeast, clearly 
confirm the connection of mitochondrial 
dynamics to longevity and apoptosis, open-
ing the possibility to attenuate age-related 
degenerative processes by selective down-
regulation of mitochondrial fission in mam-
malian tissue and organs.
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Notch signaling mediates p63-induced quiescence:  
A new facet of p63/Notch crosstalk
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Cellular quiescence, a specialized form of 
growth arrest, is a carefully controlled devel-
opmental program that is essential for the 
maintenance of normal stem cell regenerative 
potential. Accumulating evidence suggests 
that the quiescence program may be co-
opted by tumor cells, increasing their long-
term survival and decreasing their sensitivity 
to a variety of anticancer therapies. in the 
mammary gland, pathways involved in stem 
cell self-renewal include those controlled by 
p63, a p53-related transcription factor, and 
Notch, a family of proteins with diverse roles 
in development and cancer. in the september 
15th issue of Cell Cycle, Kent et al.1 provide 
new mechanistic insights into the mainte-
nance of mammary cellular quiescence. They 
demonstrate that expression of ΔNp63a, the 
predominant isoform of p63 expressed in 
mammary epithelial cells, promotes cellular 
quiescence, and they provide direct evidence 
that activation of Notch3, one of four Notch 
family members expressed in mammals, is a 
principle mediator of p63-induced quiescence 
(Fig. 1A). These findings add a new dimension 
to the already substantial and complex inter-
play between p63 and Notch signaling in the 
epithelium.
An essential role for p63 in early mammary 
gland development is evidenced by the phe-
notype of constitutive p63-null mice, which 
show a complete lack of stratified squamous 
epithelia and their derivatives, including mam-
mary glands, and die shortly after birth.2,3 This 
dramatic phenotype has been attributed in 
part to a fundamental role for p63 in main-
taining proliferative potential of stem cells 
in the epithelium,4 which is consistent with a 
contribution by p63 to stem cell quiescence. 
in the adult mammary gland, p63 expres-
sion is restricted to the basal rather than 
luminal epithelial layer, and p63 expression 
has been shown to contribute to the induc-
tion and/or maintenance of basal cell fate.5 
Remarkably similar dual roles for Notch sig-
naling in stem cell preservation and cell fate 
determination in the mammary gland have 
been described. Notably, however, whereas 
both p63 and Notch family members, includ-
ing Notch3, have been linked to self-renewal 
of stem-like cells, Notch signaling is thought to 
drive commitment toward the luminal rather 
than basal cell fate. indeed, in vivo models of 
normal mammary gland development have 
demonstrated the ability of p63 expression to 
counter Notch signaling and promote basal 
cell fate, while Notch activation drives luminal 
differentiation associated with p63 downregu-
lation (Fig. 1B).5,6 Collectively, the manuscript 
by Kent et al.1 and data cited above support 
a model involving complex, reciprocal regula-
tion of p63 and Notch in the mammary gland.
How do we reconcile experiments dem-
onstrating positive regulation vs. those show-
ing negative reciprocal regulation of p63 and 
Notch expression and function? One possible 
explanation is that Notch-stimulating and 
-repressing activities of p63 may in fact be 
occurring in different cells. For example, in 
addition to regulating expression of Notch 
itself, p63 is also known to regulate expres-
sion of Notch ligands, which could control 
Notch signaling in a non-cell-autonomous 
manner. Furthermore, selective regulation of 
different Notch family members by p63 may be 
involved, as Notch1 and Notch2 are expressed 
at higher levels in luminal rather than basal 
cells, whereas Notch3 and Notch4 are com-
parably or possibly more highly expressed in 
basal epithelial cells.6 Analysis of distinct mam-
mary cell populations derived from in vivo 
studies should help clarify the details of Notch 
and p63 cross regulation.
Further work will also be required in order 
to understand the fascinating association 
of p63 and Notch signaling pathways with 
quiescence and preservation of early stem/
progenitor cells on the one hand, and with 
proliferation and differentiation of later com-
mitted progenitors on the other (Fig. 1).4-6 
This dichotomy could again be explained 
by differential expression and functions for 
different Notch family members in distinct 
developmental stages6 or, in the case of p63, 
by differential isoform expression. Another 
possibility involves expression levels, as sug-
gested by a recent study that used an in vitro 
three-dimensional model to show that high 
Figure 1. stage-specific regulation and function of p63 and Notch signaling in the mammary 
gland. (A) Activation of Notch expression by p63 inhibits cell cycle progression, thereby promot-
ing quiescence which is associated with self-renewal of mammary stem cells. (B) in contrast, 
reciprocal inhibition of p63 and Notch signaling controls cell fate determination of bipotential 
progenitor cells along basal (p63-associated) or luminal (Notch-associated) epithelial lineages.
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Notch activity inhibits proliferation, whereas 
low Notch activity induces a hyperproliferative 
response.7 Both cellular context and other col-
laborating signal transduction pathways are 
also likely to contribute to this stage-specific 
phenotypic output of Notch and p63 activa-
tion. in this regard, it is intriguing that genetic 
evidence points to context-specific contribu-
tions of p63 and Notch to both tumorigen-
esis and tumor suppression.8,9 Unraveling the 
emerging web of crosstalk between p63 and 
Notch will be essential if we are to exploit 
the potential therapeutic benefit of targeting 
these two pathways in human cancer.
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Conversion from senescent cells to pluripotent cells by modulating  
expression of Alu retroelements
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epigenetic chromatin regulations in aging 
have been intensely studied.1 During aging, 
overall DNA methylation tends to decrease, 
although some loci are specifically meth-
ylated. Histone modifications across the 
genome are also known to be modulated 
during aging. For instance, the globular accu-
mulation of heterochromatin associated with 
methylation of histone H3 at lysine 9 and 
heterochromatin protein HP1, referred to as 
senescence-associated heterochromatic foci 
(sAHFs), was observed in senescent human 
fibroblasts.2 However, the exact roles of epi-
genetic chromatin regulations in cellular 
senescence remain elusive. As an additional 
layer of complexity, DNA damage is known to 
be accumulated during aging.
it was previously shown that DNA damage 
induced by chemical treatments can derepress 
siNe (short interspersed element) retrotrans-
posons, such as Alu, in human cells.3 wang 
et al. set out to test the possibility that DNA 
damage during aging causes derepression of 
the Alu retroelements.4 The authors employed 
the ex vivo aging system with human adult 
adipose-derived mesenchymal stem cells 
(hADsCs), and found that Alu expression is 
dramatically increased in senescent cells with 
formation of γH2AX (phosphorylated his-
tone variant H2AX) nuclear foci. The γH2AX is 
recruited to DNA damage sites and mediates 
the DNA repair process. interestingly, more 
than 60% of γH2AX peaks were assigned to 
Alu (siNe), L1 (LiNe) and LTR retrotranspo-
sons. Moreover, 53BP1, the mediator of the 
DNA damage checkpoint, is colocalized with 
a particular centromere in senescent cells. 
it is possible that retroelements associated 
with DNA damage might be clustered at 
the centromere. To support this speculation, 
cohesin and condensin, which are known to 
play roles in higher-order chromatin organi-
zation,5 bind to the Alu retroelements. it was 
previously shown that the sNF2h-chromatin 
remodeling complex loads cohesin onto the 
Alu retroelements.6 in fission yeast, RNA poly-
merase iii (Pol iii)-transcribed genes, such as 
tRNA and 5S rRNA genes, distributed across 
the genome, physically associate with cen-
tromeres.7 since Alu retroelements are also 
transcribed by Pol iii, it is possible that a simi-
lar genome-organizing mechanism governs 
both the Alu-mediated genome organization 
in human and the centromeric localization of 
Pol iii genes in fission yeast.
is Alu transcriptional activation, in fact, 
directly related to cellular senescence? 
Remarkably, the stable knock down of Alu 
transcription can convert senescent cells 
into proliferative cells (Fig. 1).4 This con-
version is concomitant with upregula-
tion of pluripotency factors Nanog and 
Oct4, implying that Alu transcription might 
be a major factor in cellular senescence, 
and that Alu repression contributes to 
pluripotency.
Alu repression can reverse the senescent 
phenotype of human cells. in the model, the 
authors proposed that upregulation of Alu 
transcription might facilitate DNA damage 
at the Alu retroelements, which, in turn, is 
detected by the DNA damage checkpoint and 
causes senescence. This study raises two inter-
esting questions. First, how is Alu transcription 
activated in senescent cells? it might involve 
hsNF2 loading to the Alu retroelements. Other 
possible mechanisms might be involved with 
dysregulation of post-transcriptional silencing 
for Alu retroelements. it was shown that Dicer1 
expression is decreased in aging-related 
macular degeneration.8 Dicer1 is essential for 
post-transcriptional gene silencing through 
the processing of transcripts into small RNAs. 
Thus, Dicer1 deficiency results in accumulation 
of unprocessed Alu transcripts, leading to Alu 
RNA toxicity and human pathology.8 second, 
can a chemical inhibitor that represses Alu 
transcription decelerate cellular aging? it was 
shown that rapamycin treatment that can 
inhibit expression of Pol iii genes, including 
Alu retroelements, decelerates senescence in 
human cells.9 in conclusion, further study 
beyond these initial experiments may lead 
to the application of pharmacological com-
pounds in order to decelerate senescence and 
cell aging in the human body.
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Figure 1. Role of Alu retroelements in cellular senescence. The schematic model shows the DAPi 
staining patterns of the nuclei in self-renewing and senescent human cells. DNA damage and Alu 
transcripts are accumulated in senescent cells. Repression of Alu retroelements by shRNA knock-
down is sufficient to convert senescent cells to self-renewing cells.
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RNA processing in a tiny transcriptome
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Mitochondria are the descendants of free-
living a-proteobacteria. Their genomes have 
shrunk to a tiny set of genes that, in humans, 
encode only 13 mRNAs, the 12s and 16s rRNAs 
and 22 tRNAs. These genes are essential, but 
they are far from sufficient to enable respi-
ration and mitochondrial gene expression. 
instead, mitochondria import cytosolic help 
in the form of hundreds of additional nuclear-
encoded factors. while the number of nuclear 
factors known to be involved in mitochondrial 
gene expression has increased sharply in the 
past few years, we know relatively little about 
the mechanistic properties of these factors. A 
case in point is the topic of mitochondrial RNA 
processing in humans: we know that human 
mitochondrial genomes are transcribed from 
three promoters that give rise to two long 
polycistronic transcripts covering the entire 
genome and a third shorter transcript encom-
passing the two rRNAs and one tRNA. These 
transcripts are broken down to yield mature 
mRNAs, tRNAs and rRNAs.
The prevailing model for how this pro-
cessing occurs is now 30 y old and, in a nut-
shell, says that the excision of tRNAs splits 
polycistronic transcripts into monocistronic 
units. This model, which is known as the tRNA 
punctuation model of human mitochondrial 
gene expression,1 implies that tRNA matura-
tion is crucial for mitochondrial RNA process-
ing. Although studies showed that tRNA end 
processing is performed in most organisms 
by RNase P (for the 5’ end) and RNase Z (for 
the 3’ end), it was long unclear which proteins 
played these roles in human mitochondria. 
Recently, however, a biochemical characteriza-
tion of mitochondrial RNase P activity uncov-
ered a non-canonical three-subunit complex 
consisting of the proteins MRPP1, -2 and  -3.2 
Furthermore, results from other studies 
suggested that eLAC2 could be the RNase 
Z homolog in humans.3 How these proteins 
affect overall RNA processing in human mito-
chondria in vivo remained unclear.
in the september 1st issue of Cell Cycle, 
Lopez sanchez et al.4 reported having investi-
gated the function of the aforementioned pro-
teins by combining classical molecular biology 
techniques with a next generation sequencing 
(NGs) analysis of mitochondrial transcripts. For 
the first time, the NGs approach allowed the 
authors to both comprehensively and quanti-
tatively examine changes in human mitochon-
drial transcript processing. They report that 
knockdown of MRPP1 and MRPP3 decreases 
the abundance of most tRNAs and, further-
more, decreases the proportion of tRNAs with 
mature 5' ends without affecting the distribu-
tion of mature 3’ ends. in contrast, knockdown 
of eLAC2 decreases the proportion of rRNAs 
with mature 3’ ends but does not affect the 
5’ ends. The authors confirm these processing 
defects using classical qRT-PCR analyses that 
demonstrate a striking overaccumulation of 
unprocessed precursor RNAs over mature tran-
scripts in the knockdown cells. These results 
provide striking experimental support for the 
hypotheses that MRPP1, MRPP3 and eLAC2 
are involved in mitochondrial tRNA maturation 
and are thus crucial to overall mitochondrial 
RNA processing. in addition to their detailed 
characterization of known factors, the authors 
also uncovered a novel general player in tRNA 
maturation, PTCD1. Although PTCD1 was pre-
viously described as associating with incom-
pletely processed tRNAs and was believed to 
be involved in regulating the abundance of 
the leucine tRNA,5 the NGs results presented 
by Lopez sanchez et al. suggest that PTCD1 
actually targets the processing of many tRNAs. 
Furthermore, the co-purification of PTCD1 and 
eLAC2 suggest that these proteins may form 
a general machine for the processing of tRNA 
3’ ends.
Given that mitochondria and, in particular, 
the genetic information encoded within mito-
chondria are key players in aging, cancer, dia-
betes and heart disease,6,7 the sanchez study 
can be seen as an exciting new jumping-off 
point for a detailed analysis of the human 
mitochondrial RNA processing machinery. 
while the overexpression experiments pre-
sented by Lopez sanchez et al. suggest that 
the investigated factors are not rate limiting 
for RNA processing in the tested cell lines and 
under the utilized conditions, future analyses 
should thoroughly test these findings in vivo. 
in addition, future work can address the press-
ing unanswered questions, which include, how 
do the identified proteins mechanistically fos-
ter RNA processing? Are they true regulators 
of gene expression? surely, this is an exciting 
time to be examining the tiny transcriptome 
of the human mitochondria!
References
1. Ojala D, et al. Nature 1981; 290:470-4; PMiD:7219536; 
http://dx.doi.org/10.1038/290470a0.
2. Holzmann J, et al. Cell 2008; 135:462-74; 
PMiD:18984158; http://dx.doi.org/10.1016/j.
cell.2008.09.013.
3. Takaku H, et al. Nucleic Acids Res 2003; 31:2272-
8; PMiD:12711671; http://dx.doi.org/10.1093/nar/
gkg337.
4. Lopez sanchez Mi, et al. Cell Cycle 2011; 10:2904-
16; PMiD:21857155; http://dx.doi.org/10.4161/
cc.10.17.17060.
5. Rackham O, et al. Nucleic Acids Res 2009; 37:5859-
67; PMiD:19651879; http://dx.doi.org/10.1093/nar/
gkp627.
6. wallace DC. Annu Rev Genet 2005; 39:359-407; 
PMiD:16285865; http://dx.doi.org/10.1146/
annurev.genet.39.110304.095751.
7. shutt Te, et al. environ Mol Mutagen 2010; 51:360-
79; PMiD:20544879.
